Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial
ConclusionGanglioside monosialic acid potentially decreases severe utidelone plus capecitabine-induced peripheral neuropathy in metastatic breast cancer, and further investigation is needed to validate the manageable efficacy of GM1 in CIPN.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT02253459.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Genetics | Neurology | Peripheral Neuropathy | Statistics | Study | Xeloda